Listed drugmakers see marketing expenses fall in H1

Korean drug manufacturers saw a contraction in their marketing outlays in the first half on a year-on-year basis, apparently hit by weaker bottom line due to the government-mandated cuts in drug prices last year.

According to a report released by Yakup.com, a pharmaceutical information portal, the combined marketing expense of 54 drug firms listed on the Korean stock market recorded 1.72 tri...